Results 191 to 200 of about 309,985 (359)

Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials. [PDF]

Virol J
Huang Y, Lin Z, Guo X, Zhang F, Wang Y, Zhang Z, Chen J, Liu L, Zhu M, Li Y, Ni M, Zhen Z, Wu Z, Ling X, Zhou S, Xi Y, Yu Y, Liang W, Zhao J, Li L, He J, Sang L.   +21 more
europepmc   +1 more source

Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay [PDF]

, 2020
Cong Zeng, John P. Evans, Rebecca M. Pearson, Panke Qu, Yi-Min Zheng, Richard Robinson, Luanne Hall‐Stoodley, Jacob S. Yount, Sonal Pannu, Rama K. Mallampalli, Linda J. Saif, Eugene M. Oltz, Gerard Lozanski, Shan‐Lu Liu   +13 more
openalex   +1 more source

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

Advanced Science, EarlyView.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann, Martijn Dijkstra, Philipp Salomon, Jamie Cowles, Anja Federa, Dina Baier, Carola Jaunecker, Iemima Semerean, Venla Karvonen, Christine Pirker, Maria Sibilia, Dietmar Herndler‐Brandstetter, Petra Heffeter, Bernhard K. Keppler, Christian R. Kowol, Walter Berger   +15 more
wiley   +1 more source

Sputnik V update: safety and neutralizing antibodies in healthy adults and adolescents. [PDF]

Front Immunol
Shuliakova IV, Grousova DM, Iliukhina AA, Dzharullaeva AS, Lubenets NL, Ordzhonikidze MK, Izhaeva FM, Erokhova AS, Zorkov ID, Azizyan VV, Boeva ZD, Reshetnikov DA, Ermolova IA, Lega VA, Kovyrshina AV, Bukhtin KM, Romanova LP, Alekseeva EI, Borzakova SN, Rachina SA, Rusanova MG, Ozharovskaia TA, Popova O, Zrelkin DI, Zubkova OV, Tukhvatulin AI, Tukhvatulina NM, Shcheblyakov DV, Favorskaya IA, Esmagambetov IB, Karpov AP, Semikhin AS, Pochtovyi AA, Naroditskiy BS, Gushchin VA, Gintsburg AL, Logunov DY.   +36 more
europepmc   +1 more source

Neutralization of lymphocyte immortalization by different strains of Epstein-Barr virus with a murine monoclonal antibody [PDF]

, 1982
George Miller, Lee Heston, Gary J. Hoffman   +2 more
openalex   +1 more source

Restriction of Individual Branched‐Chain Amino Acids has Distinct Effects on the Development and Progression of Alzheimer's Disease in 3xTg Mice

Advanced Science, EarlyView.
Protein restriction (PR) slows Alzheimer's disease (AD) in mice, and other benefits of PR are due to decreased branched‐chain amino acids (BCAAs). We show that restricting any BCAA has benefits, with sex‐ and BCAA‐specific impacts on pathology, molecular signaling, and cognition.
Reji Babygirija, Cara L. Green, Michelle M. Sonsalla, Izabelle Marie F. Le, Fan Xiao, Sarah Yandell, Mariah F. Calubag, Michaela E. Trautman, Anna Tobon, Ryan Matoska, Chung‐Yang Yeh, Charles I. Opara, Isaac Grunow, Diana Vertein, Sophia Schlorf, Bailey A. Knopf, Michael J. Rigby, David A. Harris, Mark P. Keller, Alan D. Attie, Luigi Puglielli, Cholsoon Jang, Dudley W. Lamming   +22 more
wiley   +1 more source

Cuproptosis and Disulfidptosis Converge to Empower PD‐L1 Checkpoint Therapy via Cadict‐Induced PD‐L1 Translation

Advanced Science, EarlyView.
This study introduces Cadict, an EGFR‐targeted nanodrug that co‐delivers cuproptosis and disulfidptosis inducers to overcome immune resistance. Cadict synergistically enhances tumor cytotoxicity and sensitizes cancers to ICIs by upregulating PD‐L1 via an Eif5b‐dependent translation mechanism, fostering a potent antitumor immune response and ...
Shaoqing Huang, Shiyao Song, Xinhua Zhang, Jialing Gao, Ruihan Pu, Jiatong Dai, Xiaoxue Wu, Lulu Chen, Qinghai Li, Xiaoting Liu, Qi Zhou, Mei Song, Weiling He   +12 more
wiley   +1 more source

Development of a Norway rat hepacivirus reporter for high-throughput quantification of neutralizing antibodies. [PDF]

J Virol
Kennedy MJ, Wolfisberg R, Lundsgaard EA, Thorselius CE, Collignon L, Nielsen L, Holmbeck K, Bukh J, Scheel TKH.   +8 more
europepmc   +1 more source

In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses

, 2021
Andrea Castro, Kıvılcım Öztürk, Maurizio Zanetti, Hannah Carter   +3 more
openalex   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source